

Submitted by:

**Name:** Drs. Daniel Goldstein, Allen Lichter, Mark Ratain, Ian Tannock, Len Saltz

**Company/Organization:** Value in Cancer Care Consortium (Vi3C)

**Address:** 3930 Ridgmaar Square, Ann Arbor, Michigan 48105 ([www.vi3c.org](http://www.vi3c.org))

**Telephone:** 1-646-522-9582

**Email:** [danielg3@tauex.tau.ac.il](mailto:danielg3@tauex.tau.ac.il)

**Date of request:** June 10, 2020

**NCCN Guidelines Panels:** Cutaneous Melanoma

**Specific Change:** On behalf of Vi3C, we respectfully request the *Cutaneous Melanoma Guideline Panel* to amend the NCCN guidelines to include the options of weight-based dosing of pembrolizumab (2mg/kg every 3 weeks or 4mg/kg every 6 weeks) as alternative options to fixed dosing (200mg q3w or 400mg q6w). We propose adding this to page 72 of the current guidelines, titled “Systemic Therapy Considerations.”

**Rationale:** Weight based dosing at 2mg/kg q3w and fixed dosing at 200mg q3w are considered by the FDA and the manufacturer to have equivalent safety and efficacy. Pharmacokinetic data demonstrate that 4mg/kg q6w provides acceptable trough target engagement.<sup>1</sup> For patients with body weight  $\leq 55$ kg, dosing at 2mg/kg q3w (accepting standard dose-rounding) would permit treatment with one 100mg vial, thereby reducing the drug cost in these patients by 50%. For patients with body weight  $\leq 82.5$  kg (accepting standard dose-rounding), dosing at 4mg/kg q6w would permit treatment with three 100 mg vials, reducing the drug cost in these patients by 25%.<sup>1</sup>

**As a matter of precedent,** we note that modifications of other NCCN guidelines for purposes of mitigating financial toxicity have occurred. For example, NCCN updated the prostate cancer guidelines to allow the option of dosing of abiraterone in prostate cancer at 250 mg daily with food, as an alternative to 1000mg daily without food, when financial toxicity is felt to be a major concern and/or is felt to be a potential impediment to compliance. We also note that, in 2019, the Canadian Agency of Drugs and Technologies in Health (CADTH) concluded that “2 mg/kg every three weeks, with a 200 mg upper dose cap, is the most efficient dosage to deliver target engagement of 95% based on the trough or end of dosage interval concentration.”<sup>2</sup>

**Practical Issues:** Although the manufacturer distributes the drug in 50 mg and 100 mg vial sizes in Europe, only the 100 mg vial is currently available in the United States. These large sizes would necessitate vial sharing for some patients. In some US settings this may be challenging, given that vials, once opened and refrigerated, must be used within 24 hours, thereby creating logistical obstacles. However, in high-volume settings, especially in which the payer also acts as the provider, such as the Veterans Affairs system, vial sharing would be expected to be feasible and preferable. While the NCCN guidelines originate from the USA, they also have extensive global influence, and we would expect that many healthcare systems around the world may also wish to pursue this strategy.

### Summary of literature: Initial Pharmacologic and Clinical Studies

Pembrolizumab was first approved by the FDA for advanced melanoma in 2014 at a dose of 2 mg/kg every three weeks. The initial phase 1 trial of pembrolizumab aimed to identify the maximal tolerated dose and to assess pharmacodynamics with a wide range of doses.<sup>3</sup> This study demonstrated complete target engagement with full saturation at a dose of 1 mg/kg, which was durable for at least 21 days and there was no difference in pharmacodynamics with alternative doses of 1, 3 or 10 mg/kg. Translational models of intratumor exposure predicted robust responses at doses of 2 mg/kg every 3 weeks leading to a recommended phase 2 dose of 2 mg/kg every 3 weeks, which was ultimately the first FDA approved dose. Other clinical trials and population pharmacokinetic models have clearly established that there was no difference in efficacy in the range between 2 mg/kg to 10 mg/kg.<sup>4-7</sup>

### Population Pharmacokinetic studies and FDA label changes

Recent changes in dosing strategy moved away from weight based dosing to fixed dosing, with the first fixed dose approval of 200 mg every 3 weeks coming as a result of the positive findings for *PD-L1* positive lung cancer in 2016.<sup>8</sup> Subsequent label changes recommended this dosing strategy for all adult indications. However, recognizing that the mean weight of a patient with lung cancer was 75kg, and 2 mg/kg and 200 mg fixed dose are considered equivalent by both the manufacturer and the FDA, significant financial savings can be made by using weight based dosing.<sup>9</sup> In 2020, based on pharmacokinetic modelling data, the FDA approved the fixed dose option of 400mg q6w. However, when examining the PK data, it is evident that 4 mg/kg q6w also provides suitable drug exposure.<sup>1</sup>

From the perspective of an individual and society it is reasonable to expect that weight-based dosing will lead to reduced financial toxicity while maintaining equivalent health outcomes.

### References

1. Goldstein DA, Ratain MJ, Saltz LB. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. *JAMA Oncol*. Published online May 27, 2020. doi:10.1001/jamaoncol.2020.2493
2. CADTH TECHNOLOGY REVIEW: OPTIMAL USE 360 REPORT Dosing and Timing of Immuno-Oncology Drugs. Canadian Agency of Drugs and Technologies in Health; 2019. <https://www.cadth.ca/sites/default/files/ou-tr/ho0008-dosing-timing-immuno-oncology-drugs.pdf>
3. Patnaik A, Kang SP, Rasco D, et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2015;21(19):4286-4293. doi:10.1158/1078-0432.CCR-14-2607
4. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol*. 2015;16(8):908-918. doi:10.1016/S1470-2045(15)00083-2
5. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015;372(21):2018-2028. doi:10.1056/NEJMoa1501824
6. Chatterjee M, Turner DC, Felip E, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. *Ann Oncol Off J Eur Soc Med Oncol*. 2016;27(7):1291-1298. doi:10.1093/annonc/mdw174
7. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet Lond Engl*. 2016;387(10027):1540-1550. doi:10.1016/S0140-6736(15)01281-7
8. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2016;375(19):1823-1833. doi:10.1056/NEJMoa1606774
9. Goldstein DA, Gordon N, Davidescu M, et al. A Pharmacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. *J Natl Cancer Inst*. 2017;109(11). doi:10.1093/jnci/djx063